Skip directly to content

TAGline 2016

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

TAGline Fall 2016

Health, Human Rights, and Social Justice
Maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.
 

Science and Solidarity
Using human rights to strengthen TB research and access

Who’s Responsible?
Pharma’s Obligations Under the Right to Science

Countering the Contagion of Racism Through Resistance
Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB

Beyond Tuskegee
A case for a racial justice agenda in treatment and research

Decriminalization is a Public Health Strategy
We can’t end the viral hepatitis epidemics unless we end the war on drug users

Rallying the Multitude to Free the (generic) HCV Cure
Effective responses to the burgeoning hepatitis C pandemic requires solidarity between the global North and South

Toward Health Equity
We will not end HIV as an epidemic without the expertise and leadership of Black and Latino gay and bisexual men and transgender people of color.


TAGline Spring 2016

Fair Pricing: Reclaiming Drugs for the Common Good

The way I see it, you can go down in history as the poster boy for greedy drug-company executives, or you can change the system—yeah, you.
—U.S. Representative Elijah E. Cummings (D-MD)

With these words, directed at execrated former Turing Pharmaceuticals CEO Martin Shkreli at a House Oversight and Government Reform Committee hearing on Capitol Hill this February, ranking member Elijah E. Cummings drew attention to a serious culpability problem that continues to dominate public discourse on the egregious pricing of prescription drugs in this country.

Greed and the Necessity for Regulation
The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction

PrEP Pricing Problems
A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them

The Low Cost of Universal Access
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability